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Genetic immune therapyHuman stem cell-based therapeutic intervention strategies for treating HIV infection have recently undergone
a renaissance as a major focus of investigation. Unlike most conventional antiviral therapies, genetically
engineered hematopoietic stem cells possess the capacity for prolonged self-renewal that would continuously
produce protected immune cells to ﬁght against HIV. A successful strategy therefore has the potential to stably
control and ultimately eradicate HIV from patients by a single or minimal treatment. Recent progress in the
development of new technologies and clinical trials sets the stage for the current generation of gene therapy
approaches to combat HIV infection. In this review, we will discuss two major approaches that are currently
underway in the development of stem cell-based gene therapy to target HIV: one that focuses on the
protection of cells from productive infection with HIV, and the other that focuses on targeting immune cells to
directly combat HIV infection.esearch Building, University of California Los Angeles, 615
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As we enter the fourth decade since the HIV/AIDS pandemic was
ﬁrst recognized in 1981, there still exists a strong and pressing need
for the development of novel therapeutic strategies to treat the
disease. There is currently no effective, wide-scale vaccination
strategy nor is there a practicable therapy that results in the
eradication of the virus from infected individuals. However, based
on the historically unprecedented research into this infectious
disease, the development of antiretroviral drug therapy has radically
changed the natural history of the disease throughout the world.
These therapies have signiﬁcant associated problems and ultimately
fail to result in a functional “cure” (Volberding and Deeks, 2010). Thus,
new approaches are required that can complement or replace existing
therapies that enable full control of the virus and the restoration of the
damaged immune system that HIV targets. Recent advances in the
development of stem cell-based therapeutic approaches as well as the
development of technologies that allow the genetic modiﬁcation of
these cells have provided impetus towards the creation of novel
therapeutic strategies that target HIV infection. While many of these
approaches are currently in the early stages of investigation, they
provide a new avenue that, at the very least, will lend new insights
into HIV infection and pathogenesis; and, at the very best, provide a
viable therapy that successfully treats HIV infection and has an impact
on what is a highly confounding disease.
Current HIV therapy and limitations
The current HIV therapy using combinations of antiretroviral drugs
termed highly active antiretroviral therapy (HAART) has decreased
the morbidity and mortality of HIV infected patients (Palella et al.,
1998; Volberding and Deeks, 2010). Although HAART has dramati-
cally improved the patient's quality of life, HAART requires continuous
drug administration to suppress virus production from HIV reservoirs
(Chun et al., 1999). The lifelong treatment creates complications such
as drug toxicities and side effects, adherence difﬁculties, and drug
resistance. In addition, lifelong treatment costs can be expensive. Even
under HAART, ongoing low level viremia is evident in patients
(Dinoso et al., 2009), potentially contributing to chronic inﬂamma-
tion, immune dysfunction and accelerated aging (Deeks, 2010). Long-
term HIV control and elimination of latently infected cells have
become major challenges in the HAART era (Richman et al., 2009).
Despite extensive efforts to purge residential HIV from reservoirs,
existing drug therapies do not eliminate HIV reservoirs even by drug
intensiﬁcation (Dinoso et al., 2009). In contrast, a hematopoietic
stem/progenitor cell (HSC)-based gene therapy approach would offer
continuous, long-term production of genetically engineered HIV
resistant or HIV-targeted cells and a potential to provide stable
control or eradication of HIV by a one time or minimal treatment.
Hematopoietic stem cell gene therapy approach to achieve long-term
HIV resistance
Substantial progress has been made in developing a new
therapeutic approach using gene therapy through HSCs to attempt
to confer long-term resistance against HIV (Fig. 1). HSCs are capable of
self-renewal and differentiation into all hematopoietic lineages. In
theory, gene therapy approaches that introduce protective genes
against HIV via HSCs can continuously produce their anti-HIV genes inall differentiated cells, including HIV target cells such as CD4+ T
lymphocytes and macrophages. Successful replacement of a patient's
immune system by gene modiﬁed HIV protected cells may have the
potential to minimize viral loads as well as reduce reservoirs of
infected and latently infected cells. Newly differentiated protected
cells may prevent viral production and spread from persistently
infected cells and may allow the functional restoration of the
damaged immune system. Currently, a signiﬁcant clinical beneﬁt by
HSC-based gene therapy approaches for HIV diseases has not been
achieved; however, this approach has the potential to provide long-
term control of HIV through a single treatment. If successful, gene
therapy through stem cells could free patients from lifelong daily
medications and signiﬁcantly impact their quality of life.
Protecting cells from infection: Intracellular immunization
Introduction
Over the past 20 years, researchers have developed numerous
gene-based reagents capable of inhibiting HIV infection by intracel-
lular immunization. The intracellular immunization approach to HIV
treatment intends to make HIV target cells resistant to HIV by
introducing anti-HIV genes (Baltimore, 1988). Here, we discuss anti-
HIV gene reagents by classifying them as late step inhibitors (post-
integration) and early step inhibitors (preintegration).
Late step anti-HIV gene development
Initially, anti-HIV genes were designed to inhibit HIV transcription
and translation, which occur in the late steps of the viral life cycle. The
transdominant negative HIV Rev mutant RevM10 inhibits HIV RNA
nuclear cytoplasmic transport by binding to the rev responsive
element (RRE) and interfering with Rev function (Bogerd et al., 1995).
Intrabodies against HIV Tat and trans-activating response region
(TAR) decoys inhibit HIV transcription by sequestering the Tat protein
(Mhashilkar et al., 1999; Sullenger et al., 1990). Ribozymes were
designed to cleave HIV RNA transcripts by enzymatic activities
(Amado et al., 2004; Sarver et al., 1990). Antisense RNAs were
designed to hybridize with HIV RNA transcripts and inhibit HIV
expression and/or replication (Goodchild et al., 1988; Humeau et al.,
2004; Levine et al., 2006). Since the discovery of RNA interference
(RNAi) (Fire et al., 1998), many small interfering RNAs (siRNA)
directed to HIV RNA sequences have been developed. siRNAs directed
against various HIV RNA sequences inhibited HIV in various
experimental settings (Capodici et al., 2002; Lee et al., 2002; Novina
et al., 2002; Park et al., 2003). Oneweakness of the RNAi approachwas
recognized when HIV quickly escaped from siRNAs with minimum
mutations (Boden et al., 2003; Senserrich et al., 2008). Efforts to make
combinations of siRNAs targeting multiple HIV RNA sequences
prevented emergence of escape mutations (ter Brake et al., 2006).
All of these anti-HIV genesmediated efﬁcient HIV inhibition in various
experimental settings. Some of the anti-HIV genes (RevM10, env
antisense, ribozymes, RRE decoy and tat/rev siRNA) were tested in
clinical trials, as discussed in more detail below.
Early step anti-HIV gene development
Several labs have developed HIV inhibitors that are designed to
target HIV at early life cycle steps before genome integration.
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Anti-HIV factor
3’LTR 
1. Clone and characterize
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4. Transduction of CD34 + cells
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Fig. 1. Schematic illustrating HSC-based gene therapy approaches to treat HIV infection. The anti-HIV factor (such as a siRNA to CCR5 or a molecularly cloned anti-HIV TCR) is cloned
and characterized (1) and made into lentiviral vector (or other form enabling genetic transduction of target cells) (2). HSCs are mobilized from the bone marrow of HIV infected
individuals and peripheral blood mobilized CD34+ cells are obtained by apheresis and cell sorting (3). CD34+ cells enriched with HSCs are then genetically transduced with the
anti-HIV factor (4), and the cells are then reinfused back into the individual (5). Following infusion, the anti-HIV gene containing HSCs should migrate to the bone marrow where
they take up residence as long-term hematopoietic progenitors. Anti-HIV gene containing cells protected from infection should undergo selection by HIV in the body and/or cells
engineered to target HIV should respond to the virus and proliferate (6). The effects of this are protection of anti-HIV gene containing cells (7a) or directed targeting of HIV or HIV
infected cells by anti-HIV gene expressing cells (7b), resulting in the regeneration of antiviral immune responses and targeted eradication of HIV.
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strategies that inhibit late steps in the viral life cycle. They can
protect cells from the establishment of chronic HIV infection. These
protected cells may have selective advantage against being killed by
HIV-mediated cytotoxicity. Further, inhibitors that work on steps
before reverse transcription have a better chance of preventing HIV
mutations because they stop the virus prior to themutagenic effects of
the reverse transcription process. There is ongoing investigation into
gene-based reagents that are 183 capable of inhibiting HIV cell surface
receptors, HIV fusion, or 184 incoming virions.
HIV receptor inhibition
Gene-based reagents to reduce HIV receptors (CD4, CCR5 or
CXCR4) have been developed using ribozyme, antisense RNAs,
intrabodies and siRNAs (Anderson et al., 2003; Bai et al., 2001;
Qureshi et al., 2006; Zhou et al., 2004). Among HIV receptor inhibitors,
CCR5 inhibitors provide great promise to protect cells from HIV
without adversely affecting human health, because individuals who
lack CCR5 expression due to the homozygous Δ32/Δ32 deletion in theCCR5 gene are highly resistant to HIV infection and have an
apparently normal health status (Alkhatib et al., 1996; Dragic et al.,
1996; Liu et al., 1996; Mummidi et al., 1998; Smith et al., 1997).
Heterozygous individuals with a 50% decrease in CCR5 surface
expression have lower plasma viral load and a substantially prolonged
course of HIV disease (Dean et al., 1996; Rappaport et al., 1997).
Recently, the proof of concept for HIV stem cell therapy using CCR5
defective HSC treatment was demonstrated by the “Berlin patient,”
who demonstrated long-term control of HIV infection following
myeloablation and an allogeneic bone marrow transplant with CCR5
defective cells (Hutter et al., 2009). In this report, Hutter and
colleagues intentionally selected a human leukocyte antigen (HLA)
matched CCR5 Δ32/Δ32 homozygous bone marrow donor to treat a
HIV+ patient with acute myelogenous leukemia. Intensive bone
marrow ablation and stem cell transplants resulted in complete
replacement of the patient's peripheral blood system with the CCR5
Δ32/Δ32 homozygous donor cells. Though the patient had discon-
tinued HAART after the bone marrow transplant, the patient's HIV
plasma viral load and HIV proviral DNA have remained negative for
more than 3.5 years. This case provides the ﬁrst well documented
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paper by the same group provided further evidence of a cure (Allers et
al., 2010). In this report, the same patient's blood system remained
completely replaced with cells derived from the CCR5 Δ32/Δ32 donor
cells and the host-derived CCR5+ macrophages in the Gut became
undetectable after 24 months. HIV DNA and RNA remained undetect-
able in plasma and peripheral blood mononuclear cells. One of the
major limitations of this strategy is the difﬁculty of identifying HLA
matched donors with the CCR5Δ32/Δ32 homozygous deletion. This is
confounded by the fact that the CCR5 Δ32/Δ32 homozygous deletion
exists naturally in only one percent of the Caucasian population, and is
rarer in other ethnic populations (Lucotte, 1997). In all, this report of a
functional cure for HIV, although not practicable for widespread use as
a viable therapeutic strategy, is an exciting observation and forms the
foundation for strategies that target the CCR5molecule in treating HIV
infection.
Stable CCR5 inhibition by gene reagents
Gene therapy strategies enable the use of genetically modiﬁed
HSCs for autologous transplant in patients. Several groups have
developed gene therapy strategies using ribozyme, intrabodies,
shRNA or zinc ﬁnger nuclease aiming to make cells resistant to HIV
by CCR5 inhibition.
Ribozyme directed to CCR5
Feng and colleagues (2000) developed a hairpin ribozyme against
CCR5. They transduced the CCR5 ribozyme by recombinant adeno-
associated viral vector into human PM1 cells and demonstrated
reduced CCR5 expression and CCR5 tropic HIV replication inhibition in
vitro. In independent studies, Cagnon and Rossi (2000) developed a
CCR5 ribozyme. This ribozyme was combined with a HIV tat/rev
shRNA and a TAR decoy in a lentiviral vector and was recently tested
in a phase I clinical trial as described in greater detail below (DiGiusto
et al., 2010).
Intrabodies to inhibit cell surface CCR5 expression
Using a different approach, Steinberger and colleagues (2000)
developed a CCR5-speciﬁc single-chain intrabody that efﬁciently
reduced CCR5 cell surface expression by retaining the CCR5 protein
in the endoplasmic reticulum. Intrabody expressing PM-1 cell lines,
primary CD4+ T cells, and human thymocytes derived from
thymus/liver implants generated in the humanized non-obese
diabetic-severe combined immunodeﬁcient (NOD-SCID-hu) thy-
mus/liver (thy/liv) model were protected from CCR5 tropic HIV
infection by CCR5 surface down-regulation (Swan et al., 2006).
Further, CCR5 blocked cells were selected by HIV infection during
dendritic cell mediated R5 tropic HIV challenge experiments
in vitro.
RNA interference to knock down CCR5
Several groups have developed shRNAs to stably knock down CCR5
expression (Anderson and Akkina, 2005; Anderson et al., 2009;
Butticaz et al., 2003; Kim et al., 2010; Shimizu et al., 2010). Lentiviral
vector transduction of CCR5 directed shRNAs efﬁciently reduced CCR5
expression and conferred resistance against CCR5 tropic HIVs in vitro
(Anderson and Akkina, 2005; Anderson et al., 2009; Butticaz et al.,
2003; Kim et al., 2010; Shimizu et al., 2010). However, we and others
recognized that overexpression of shRNA using a U6 RNA polymerase
III promoter could induce cytotoxicity in human primary T lympho-
cytes (An et al., 2006; Kiem et al., 2010; Lo et al., 2007). This
cytotoxicity could be caused by saturation of endogenous micro (mi)
RNA biogenesis (Grimm et al., 2006, 2010). To avoid the cytotoxicity,we lowered shRNA expression by utilizing a transcriptionally
weaker H1 RNA polymerase III promoter. To achieve robust CCR5
knockdown with the H1 promoter, we selected a potent CCR5
shRNA from an enzymatically generated shRNA library directed to
CCR5 (An et al., 2006). This optimization resulted in up to 25-fold
CCR5 reduction in human primary T lymphocytes and CD34+ cell-
derived macrophages without toxic effects in vitro (An et al., 2007;
Liang et al., 2010). CCR5 shRNA transduced CD34+ cells trans-
planted into myeloablated rhesus macaques resulted in a stable 3-
to 10-fold reduction in CCR5 expression in peripheral blood T
lymphocytes in vivo. No apparent adverse effects due to the shRNA
were evident in transplanted macaques for 3 years. Importantly,
these cells were less susceptible to simian immunodeﬁciency virus
infection ex vivo than were control cells (An et al., 2007). We
further examined in vivo human CCR5 knockdown in a recently
developed humanized NOD/SCID/IL2rγnull (NSG) bone marrow/
liver/thymus (BLT) transplanted mouse model (Shimizu et al.,
2010). Lentiviral vector transduction of the CCR5 shRNA into
human fetal liver CD34+ cells and subsequent transplant in the
BLT humanized mouse resulted in stable CCR5 down-regulation in
the transplanted thy/liv implant, and in primary and secondary
lymphoid organs including the gut-associated lymphoid tissue,
which is the major site of HIV replication in humans (Brenchley et
al., 2004). CCR5 expression was efﬁciently reduced up to 5-fold in
human CD4+ T cells and CD14+/CD33+ monocytes/macrophage
populations. The shRNA-mediated CCR5 knockdown had no
apparent adverse effects on T cell development as assessed by
polyclonal T cell receptor Vβ family development and naïve/
memory T cell differentiation. CCR5 knockdown continued to be
observed in mice receiving a secondary transplant from the bone
marrow of the mice receiving the ﬁrst set of CCR5 shRNA modiﬁed
CD34+ HSCs. This suggests long-term engraftment and self-
renewal potential by the shRNA transduced HSCs. Down-regulation
of CCR5 was sufﬁcient to protect T cells from HIV challenge ex vivo.
These studies demonstrated the feasibility and potential of
lentiviral vector-mediated delivery of CCR5 shRNA through HSC
transplant as a means of intracellular immunization for the
treatment of HIV.
Zinc ﬁnger nuclease to disrupt the CCR5 gene
A recent novel approach to disrupt the CCR5 gene was developed
by using engineered zinc ﬁnger nuclease proteins (ZFNs) (Perez et al.,
2008). ZFNs are comprised of custom-made zinc ﬁnger DNA binding
domains fused to an endonuclease fok I domain to generate a double-
strand break at a speciﬁc DNA target site. When these double-strand
breaks are repaired, deletions and insertions can be introduced at the
site of cleavage through a non-homologous end joining (NHEJ)
cellular DNA repair mechanism. Holt and colleagues (2010) optimized
the method to introduce CCR5 gene speciﬁc ZFNs into human cord
blood and fetal liver derived CD34+ cells. The group achieved a mean
disruption rate of approximately 17% of the total CCR5 alleles in the
population of CD34+ cells. They estimated that 5–7% of ZFNs treated
cells would be mutated at both alleles. ZFN treated CD34+ cells were
transplanted into irradiated neonatal NSG mice. ZFN treated CD34+
cells reconstituted human lymphocytes in systemic lymphoid organs
in the mice. Mice were subsequently challenged with highly
pathogenic CCR5 tropic HIV-1BaL. Remarkably, CCR5 negative CD4+
T cells were rapidly selected in the HIV challenged mice. Genomic
DNA PCR analysis of the CCR5 gene revealed accumulations of
polyclonal insertion/deletion mutations at the ZFN target sites. Viral
load decreased over time in the ZFN treated mice. These results were
highly remarkable in that the relatively small fraction of CCR5 gene
disrupted cells can be selected in vivo in CCR5 tropic HIV-1 infected
NSG humanized mice, suggesting protection of these cells from
infection.
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In another strategy that targets HIV entry, Egelhofer and
colleagues (2004) developed a HIV fusion inhibitor, termed C46,
which can be stably expressed using retroviral/lentiviral vectors. C46
is derived from the C-terminal heptad repeat of HIV gp41. It blocks
HIV fusion by binding to the N terminal coiled coil domain of HIV gp41
fusion intermediate and prevents the six-helix bundle formation,
analogous to the FDA approved soluble peptide drug enfuvirtide (T20)
(Lalezari et al., 2003). C46 expression on the cell surface inhibited HIV
replication more than 2 logs in cell lines and more than 1 log in
primary human T lymphocytes (Perez et al., 2005). A recent report
conﬁrmed the robustness of C46 over tat/rev speciﬁc shRNAs and a
long antisense RNA targeted against HIV envelope (termed VRX496)
(Kimpel et al., 2010). C46 expressing cells were effectively selected
after HIV challenge in vitro. The safety of C46 has been tested in a
phase I clinical trial where autologous T cells transduced with a
retroviral vector expressing C46 were infused into patients, and
showed no gene therapy related adverse effects (van Lunzen et al.,
2007).
Host restriction factors as anti-HIV reagents for gene therapy
Recent investigations of cross primate HIV permissiveness iden-
tiﬁed natural host HIV restriction factors (Strebel et al., 2009). In
rhesus macaques, it was found that TRIM5α inhibits HIV infection
(Stremlau et al., 2004). Although the precise inhibitory mechanism is
under investigation, TRIM5α inhibits HIV through binding the capsid
of incoming virions (Strebel et al., 2009). Further, TRIM5α can inhibit
HIV infection when it is expressed in human cells as a transgene
(Stremlau et al., 2004). However, rhesus TRIM5α is not suitable for
gene therapy because of the potential immunogenicity in humans.
Human–rhesus chimeric TRIM5α and a single amino acid substituted
human TRIM5α (R322P) were created through the investigation of
active domains responsible for the HIV restriction (Stremlau et al.,
2005; Yap et al., 2005). These minimally modiﬁed human TRIM5αs
inhibit HIV (Li et al., 2006). Anderson and Akkina (2008) demon-
strated CD34+ cell transduction of human–rhesus chimeric TRIM5α
using a lentiviral vector and thymocyte differentiation in thy/liv tissue
in the SCID-hu thy/liv mousemodel. The resultant human thymocytes
were protected from ex vivoHIV challenge. In another instance of host
restriction, owl monkey cells block HIV infection by an endogenous
TRIM5α–cyclophilinA fusion protein (TRIMcyp) (Sayah et al., 2004).
The Owl monkey TRIMcyp gene was created by a LINE-1 mediated
retrotransposition of cyclophilinA cDNA into TRIM5α gene locus.
Interestingly, the TRIMcyp fusion genes were created by independent
retrotransposition events in Old World and New World primates,
suggesting critical roles of TRIMcyp proteins as host restriction factors
in primates (Brennan et al., 2008; Newman et al., 2008; Virgen et al.,
2008;Wilson et al., 2008). Human genome does not carry endogenous
TRIMcyp to restrict HIV. Neagu and colleagues (2009) recently
engineered a human TRIMcyp aiming to use it as a human gene
therapy reagent. Human TRIMcyp potently inhibited HIV in human
CD4+ T cells and macrophages in vitro and in vivo in human TRIMcyp
transduced PBMCs transplanted into Rag2­/­γc­/­ mice. Other host
HIV restriction factors that could be potentially utilized as gene
therapy reagents are APOBEC 3G (Sheehy et al., 2002), APOBEC 3F
(Holmes et al., 2007) and Tetherin (Neil et al., 2008). However, HIV is
naturally equipped with the vif and vpu proteins to counteract these
host restriction factors. Several researchers developed vif resistant
APOBEC 3G by a single amino acid substitution at D128K (Bogerd
et al., 2004; Schrofelbauer et al., 2004; Xu et al., 2004). Gupta and
colleagues (2009) developed a vpu resistant Tetherin by a single
amino acid substitution at T45I. These HIV accessory gene resistant
HIV restriction factors can be gene therapy candidates because of their
resistance to the HIV counter attack. Other cellular genes that restrictHIV infection were identiﬁed by cDNA screenings. Mov10 over-
expression inhibits HIV at multiple steps (Burdick et al., 2010; Furtak
et al., 2010). Truncated poly adenylation factor 6 (CPSF6) inhibits HIV
nuclear entry by capsid binding (Lee et al., 2010). Recent intensive
investigations aimed at better understanding of host factors and HIV
interaction may identify novel host restriction factors near future. The
ongoing efforts to increase the list of anti-HIV genes may provide new
strategies to inhibit HIV by a gene therapy approach.
Combinational anti-HIV strategy to produce highly HIV resistant cells
and prevent escape mutations
Effective gene therapy applications against HIV disease will likely
require a combination of multiple reagents directed against HIV.
Single anti-HIV therapy will likely fail due to the development of
escape mutations in the virus that confer resistance to the therapy.
Emergence of CXCR4 and dual tropic HIVs will be a concern in the case
of CCR5 inhibitors. Utilizing the same rationale as combination
antiretroviral therapy, it would be important to develop gene therapy
strategies to protect target cells with combinations of anti-HIV genes
to inhibit multiple steps in the viral life cycle. With this approach,
several groups have incorporated multiple anti-HIV genes into a
single lentiviral vector (Anderson and Akkina, 2008; DiGiusto et al.,
2010; Kiem et al., 2009; Schopman et al., 2010). Combinations of anti-
HIV genes were designed to target distinct steps in the viral life cycle
to increase the antiviral effect but were also aimed to block the
emergence of resistant HIVs. Multiple shRNAs targeting different sites
of HIV transcripts were combined within a lentiviral vector (Li et al.,
2005; Schopman et al., 2010; ter Brake et al., 2006). The combination
of three RNA reagents (HIV tat/rev shRNA, TAR decoy and CCR5
ribozyme) was transduced into human CD34+ cells which were then
differentiated into monocytes in vitro (Li et al., 2005) and thymocytes
in the SCID-hu thy/liv mouse model (Anderson et al., 2007). The
resultantmonocytes and human thymocytes were protected fromHIV
infection ex vivo (Li et al., 2003; ter Brake et al., 2006). These studies
provided the preclinical data for a recent phase I clinical trial using the
triple anti-RNA combination vector in AIDS lymphoma patients (see
below) (DiGiusto et al., 2010). Using a different approach, a triple
combination of CCR5 shRNA, a human/rhesus chimeric TRIM5α, and a
TAR decoy was expressed from a lentiviral vector. This antiviral RNA
combination efﬁciently inhibited HIV replication in CD34+ cell-
derived macrophages in vitro (Anderson et al., 2009). In a separate
study, a combination of CCR5 shRNA and a human/rhesus chimeric
TRIM5α was induced into induced pluripotent stem cells (iPSc) by a
lentiviral vector and successfully differentiated through CD133+ cells
into HIV resistant macrophages in vitro (Kambal et al., 2010). A
membrane anchored fusion inhibitor C46 andmultiple tat/rev shRNAs
were further combined in a lentiviral vector (Kiem et al., 2009). While
many of these studies are promising, it is expected that more effective
combinations will be developed with newly identiﬁed anti-HIV genes
in the future.
Clinical trials
Several anti-HIV HSC-based gene therapy protocols have been
tested in clinical trials. Most clinical trials were phase I studies aimed
at evaluating the safety and feasibility of anti-HIV gene transduced
autologous hematopoietic stem/progenitor cell transplantation in
patients. In early trials, transdominant RevM10 (Kang et al., 2002;
Podsakoff et al., 2005), RRE decoy (Kohn et al., 1999), or an anti-HIV
ribozyme (Amado et al., 2004) was introduced into patient's CD34+
cells with Moloney murine leukemia virus based gammaretroviral
vectors. In summary, all of these phase I clinical studies demonstrated
safety and feasibility of the procedures. Gene transfer and stem cell
transplantation were well tolerated in all clinical trials and no
signiﬁcant adverse events have been observed. In all of these studies,
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patients. However, the gene marking levels were too low to achieve
clear therapeutic beneﬁts.
Mitsuyasu and colleagues recently reported the ﬁrst phase II
clinical trial of an anti-HIV gene therapy (Mitsuyasu et al., 2009). This
trial involved 74 subjects enrolled in randomized, double-blind and
placebo-controlled groups in a multi-centre trial. A murine gamma
retroviral vector was used to transduce a tat/vpr speciﬁc ribozyme into
granulocyte-colony stimulating factor (G-CSF) mobilized peripheral
blood CD34+ cells. Cells were genetically modiﬁed ex vivo and
reinfused back into the patients without bone marrow conditioning.
This procedure did not result in apparent adverse events. Ribozyme
DNA and RNA were detectable in 94% of patients but gradually
declined to 7% of patients 100 weeks following treatment. Although
the levels of ribozyme DNA and RNA were low, lower viral loads and
higher CD4+ cell counts were observed in the ribozyme group. These
results suggest a marginal effect in the anti-HIV ribozyme group. This
study demonstrated a proof of concept that anti-tat/vpr ribozyme
transduced autologous HSCs transplanted in humans is safe and has a
capability to produce gene modiﬁed cells in a large numbers of
human subjects.
In themost recent clinical study, a triple combination of an anti tat/
rev shRNA, a TAR decoy and an anti-CCR5 ribozymewas introduced in
AIDS lymphoma patients through HSC transplant (DiGiusto et al.,
2010). This is the ﬁrst clinical trial applying a lentiviral vector for anti-
HIV gene transduction into patient CD34+ cells. Four AIDS lymphoma
patients underwent myeloablative conditioning and anti-HIV gene
transduced CD34+ cell infusion. The team infused unmanipulated
CD34+ cells into the patients to ensure safety. Gene marking in
peripheral blood mononuclear cells was low at 0.02–0.32% of the cells
during the follow-up period up to 24 months and the RNA transgenes
were detectable by PCR. The low levels of vivo gene marking might be
caused by the safety transplant procedure with co-infusion of
genetically unmodiﬁed cells and resultant dilution of the gene
modiﬁed CD34+ cells. Another possibility is that high expression of
shRNA from the transcriptionally strong U6 promoter might have
caused cytotoxicity. Their in vitro gene tracking experiment resulted
in a decline of vector DNA copies in transduced CD34+ cells within
4 weeks. These results suggest a growth disadvantage of vector
transduced CD34+ cells. We and other reported that overexpression
of shRNA from the U6 promoter can induce cytotoxicity in human T
lymphocytes (An et al., 2006; Kiem et al., 2010; Lo et al., 2007). shRNA
utilize the endogenous microRNA pathway to mature and therefore
may interfere with miRNA biogenesis. Therefore, the level of shRNA
expression must be carefully optimized. Switching to a transcription-
ally weaker H1 promoter to minimize shRNA expression may provide
stable maintenance of shRNA expressing cells. Further optimizations
in the vector design and transplant protocol may improve the
efﬁciency of gene modiﬁed cells in the future trials. In summary,
this clinical trial provided theﬁrst time usage of a lentiviral vectorwith
a triple combination of anti-HIV genes through stem cell transplant in
AIDS related lymphoma patients.
Summary of intracellular HSC therapeutic protection strategies
Stem cell-based gene therapy approaches hold great potential for
controlling HIV infection through a single treatment. The challenge of
achieving therapeutic levels of genetically modiﬁed cells for patient
transplants cell in clinical trials remains a major obstacle. Current
gene therapy technologies have reached the point where an HSC-
based gene therapy is able to provide therapeutic beneﬁts to single
gene deﬁciency diseases. Examples of diseases where investigators
have observed effective single gene therapies include adenosine
deaminase deﬁciency severe combined immunodeﬁciency (ADA
SCID) and X-linked SCID, where gene corrected cells have strong in
vivo selection in gene-corrected HSC transplanted patients (Aiutiet al., 2009; Cavazzana-Calvo et al., 2000; Gaspar et al., 2004). In HIV
single gene therapies, cells expressing anti-HIV genes are predicted
to be selected due to resistance to HIV-mediated T cell killing.
The recent success of gene therapy clinical trials using lentiviral
vectors for the treatment of adrenoleukodystrophy (ALD) patients
provided great promise of this vector system to repopulate the human
hematopoietic system with genetically modiﬁed cells (Cartier et al.,
2009). In the clinical trial, 9–14%of theperipheral blood cells express the
ALDtransgeneproduct andgene correctedmicroglial cellsmigrated into
the brain and stopped progressive demyelination. However, a recent
thalassaemia stem cell-based gene therapy using a lentiviral vector
provides us a cautionary tale (Cavazzana-Calvo et al., 2010). In one
individual, the treatment achieved the criteria for clinical beneﬁt but
this was achieved by a single cell clonal out-growth in the erythroid
population caused by the overexpression of high mobility group AT-
hook 2 (HMGA2) via vector insertion into control elements of the gene.
The clonal growth was not a malignancy and it is not clear whether this
event is a unique case in the erythroid lineage. This thalassaemia
example illustrates the notion that we currently do not have enough
experience with lentiviral vectors in clinical trials to be certain of their
safety. Further investigationwill showwhether lentiviral vectors can be
usedasanefﬁcient and safe vector delivery system forHIV gene therapy.
A non-viral vector approach using a CCR5 directed zinc ﬁnger nuclease
showed great promise in a humanized mouse model (Holt et al., 2010),
though the ﬁdelity of CCR5 disruption and off target gene disruptions
need to be fully investigated with a genome-wide analysis.
Successful application of stem cell-based gene therapy strategies
for HIV infection requires further investigation and development of
effective anti-HIV genes, efﬁcient gene delivery vehicles, a greater
understanding of stem cell biology, and a safe and effective bone
marrow transplant procedure. Our hope is to provide a long-term
control of HIV infection by a single treatment using stem cell-based
gene therapy in the near future.
Engineering HIV immunity
Introduction
In addition to developing HSC gene therapies to protect cells from
infection with HIV, there are efforts to “engineer” resultant immune
cells to speciﬁcally target and kill HIV in the body. As a basis for these
approaches, antiviral immune responses towards HIV are naturally
generated in most affected individuals; however, in the large majority
of cases this response is insufﬁcient at preventing replication and
clearing the virus from the body. In the natural course of HIV infection,
the levels of virus in the body following the acute stage represent the
ongoing struggle between natural immunity and the virus's ability to
replicate and evade these responses. Therapeutic intervention strat-
egies, while largely successful in lowering the levels of virus and
prolonging disease progression, are currently incapable of eradicating
the virus and repairing the damage done to the immune system by the
infection. Pertaining to this, there is a strong demand for new and
novel strategies that augment or enhance natural antiviral immune
responses and allow reconstitution of other virally perturbed aspects
of immunity.
Immune therapy for HIV infection
While the potential beneﬁts of immune therapy for HIV infection
utilizing a stem cell-based gene therapy approach are discussed
below, it is important to ﬁrst discuss the rationale behind therapeutic
strategies that attempt to enhance natural immune responses against
the virus. The ultimate goal of all of these strategies is to manipulate
antiviral immune responses to eradicate the virus from the body. A
fundamental problem in HIV infection is that the virus does not
possess the immunogenicity to elicit adequate protective responses.
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confounding factor in attempts to develop an effective preventative or
therapeutic vaccine (McElrath and Haynes, 2010). In addition, HIV
attacks the immune system itself and actively subverts it through a
variety of mechanisms that further contribute to viral persistence
(reviewed by Trono et al., 2010).
A relatively new focus has been to develop strategies that are
directed at manipulating virus-speciﬁc humoral and/or cellular
immune responses in hopes of overcoming these barriers to allow
immune suppression and clearance. Relatively simple strategies
aimed at enhancing antiviral humoral immune responses have
demonstrated that passive immunization of rhesus macaques with
neutralizing antibodies is protective against simian immunodeﬁcien-
cy virus (SIV) or simian–human immunodeﬁciency virus (SHIV)
challenge and is associated with lower viral loads in infected animals
(Baba et al., 2000; Hessell et al., 2009; Kramer et al., 2007; Mascola
et al., 2000; Ng et al., 2010; Shibata et al., 1999). In humans, passive
administration of HIV-speciﬁc neutralizing monoclonal antibodies
resulted in delay of viremia following cessation of antiretroviral
therapy (Mehandru et al., 2007; Trkola et al., 2005). While recent data
strongly suggest that humoral immunity and neutralizing antibodies
play an important role in controlling the levels of virus in chronic HIV
infection (Huang et al., 2010), enhancing these responses could be
therapeutically beneﬁcial.
Efforts have also been made to enhance existing virus antigen-
speciﬁc cellular immunity in people infected with cytomegalovirus
(CMV) and Epstein–Barr virus (EBV) by expanding virus-antigen-
speciﬁc cytotoxic T lymphocytes (CTLs) ex vivo followed by subse-
quent infusion. This approach has been demonstrated to be relatively
safe and effective at enhancing T cell immunity to these viruses and
virally transformed cells in vivo (Bollard et al., 2004; Heslop et al.,
2010; Riddell et al., 1992). Ex vivo expansion of autologous HIV-
speciﬁc CTL from infected individuals has been demonstrated to
produce cells that retain their HIV-speciﬁc lytic function and migrate
to sites of HIV replication in the lymph nodes (Brodie et al., 1999,
2000; Lieberman et al., 1997). These cells transiently lowered the
levels of productively infected CD4+ T cells. However, they did not
have a signiﬁcant effect on lowering viral loads and appear to persist
for a relatively short period of time following infusion (Brodie et al.,
1999, 2000). The inability of these cells to have a signiﬁcant effect on
viral loads is likely due to the functional perturbation of these cells
prior to ex vivo expansion by an altered immune environment
resultant from HIV infection. The lack of persistence of these
adoptively transferred cells is likely due to immune exhaustion in
the presence of ongoing viral antigenic exposure. These cells likely
lack full functional competency and altered effector function and may
not represent the numbers necessary to have any effects on enhancing
the CTL response when infused into the individual. However, ex vivo
expansion and adoptive transfer of antigen-speciﬁc cells appear to be
more successful when targeting malignancy related antigens where
perturbations in the immune environment are not as dramatic as they
are in the context of HIV infection (Berry et al., 2009; DiGiusto and
Cooper, 2007; June, 2007; Rosenberg, 2004; Rosenberg et al., 2008;
Zhou et al., 2005). A methodology to generate large numbers of
functionally competent HIV-speciﬁc CTL would be a desirable strategy
to enhance CTL responses against HIV. These adoptive strategies and
the success in the targeting of other viral antigens provide impetus
towards the development of strategies that involve genetic enhance-
ment of immune responses towards HIV.
Engineering antiviral immunity—genetic vaccination for HIV infection
Gene therapy based approaches that program the immune
response to target HIV are undergoing a period of rapid growth and
interest. Several approaches aimed at enhancing humoral and/or
cellular antiviral immune responses are in various phases ofdevelopment. Approaches that rely on “redirecting” peripheral
immune cells to target HIV infection are the most developed to this
point, with the technology having moved further along and with
several clinical trials either completed or in progress (reviewed by
June et al., 2009; Rossi et al., 2007). A primary reason for this is,
simply, that peripheral cells are relatively easy to obtain and
manipulate. Stem cell-based approaches that produce immune
cells that target viral infection are a newer concept and are more
difﬁcult to perform, with most of the preliminary development
occurring in mouse systems as proof-of-principle studies (Rossi
et al., 2007). However, as will be discussed, there are potentially
signiﬁcant advantages in using stem cell-based approaches to
engineer antiviral immune responses and their development is
rapidly advancing.
Peripheral “redirection” of antiviral immunity
Peripheral blood T cells, which are particularly suitable for
genetic manipulation, have been the focus of most efforts to date to
“redirect” cells to target HIV infection. Studies have involved the
utilization of peripheral T cells that have been genetically altered
to express a chimeric molecule or a molecularly cloned T cell
receptor (TCR) that targets cells to HIV antigens (Clay et al., 1999;
Cooper et al., 2000; Deeks et al., 2002; Hofmann et al., 2008; Joseph
et al., 2008; Miles et al., 2006; Mitsuyasu et al., 2000; Roberts et al.,
1994; Varela-Rohena et al., 2008; Walker et al., 2000; Yang et al.,
1997). There were early studies and clinical trials based on
redirecting T cells using a chimeric receptor that has the gp120
binding domain of the human CD4 molecule that is fused to the
zeta chain signaling domain of T cell receptor, termed a universal
T cell receptor (UTR) (Deeks et al., 2002; Mitsuyasu et al., 2000;
Roberts et al., 1994; Walker et al., 2000; Yang et al., 1997). This
chimeric receptor T cell redirection approach avoids problems
associated with human leukocyte antigen (HLA) restriction by an
antigen-speciﬁc TCR and would allow more broad recognition of
virally expressing cells. The clinical studies, in sum, showed
persistence of cells harboring the chimeric transgene for more
than 1 year. One study demonstrated rises in CD4 T cell levels in
people receiving ex vivo expanded autologous T cells and modest
decreases in viral reservoirs in HIV infected individuals receiving
the UTR versus control (Deeks et al., 2002). Several other
approaches that utilize chimeric receptors to redirect T cells to
target malignancy related antigens have been performed to varying
degrees of success (reviewed by June et al., 2009; Sadelain et al.,
2009), and thus remain a viable option to target antigen-
expressing cells.
In addition, studies have been performed to redirect peripheral T
cells to express a molecularly cloned TCR speciﬁc to HIV (Cooper et al.,
2000; Hofmann et al., 2008; Joseph et al., 2008; Miles et al., 2006;
Varela-Rohena et al., 2008). This approach involves molecularly
cloning an HLA-restricted, peptide speciﬁc TCR from reactive T cells
from an infected individual and subsequentmodiﬁcation of peripheral
cells by retroviral vectors (Cooper et al., 2000), lentiviral vectors
(Joseph et al., 2008; Varela-Rohena et al., 2008), or RNA electropora-
tion (Hofmann et al., 2008). All of these approaches resulted in
functional expression of the transgenic HIV-speciﬁc TCR which
redirected the transduced peripheral CD8+ T cells in vitro and (in
one case) in vivo in humanized SCID mice (Joseph et al., 2008), to
respond to HIV. This approach has been used to successfully redirect
cells to target malignancy related antigens, in particular the MART-1
melanoma antigen (Clay et al., 1999; Johnson et al., 2006; June et al.,
2009; Morgan et al., 2010, 2003) and has proven to be safe in patients
and resulted in clinical regression of metastatic melanoma lesions
(Morgan et al., 2006). In HIV infection, there are efforts to “enhance”
this redirection approach by modifying peripheral cells using high-
afﬁnity TCRs molecularly cloned, modiﬁed, and selected for higher
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speciﬁc CTL responses (Varela-Rohena et al., 2008). These high-
afﬁnity TCRs (in this case speciﬁc to the relatively conserved, HLA-
A*0201-restricted, p17 Gag SLYNTVATL (SL9) viral peptide) appear to
have an enhanced functional ability in producing polyfunctional cells
that are capable of suppressing viral replication of wild-type and
naturally occurring SL9 escape variants. A phase 1 clinical trial of this
approach is currently underway (see http://clinicaltrials.gov/show/
NCT00991224). This or similar approaches that attempt to redirect
peripheral T cells to target cells expressing lower levels of antigen or
to constrain viral evolution could be beneﬁcial in lowering viral loads
or at least provide further insight as to the constraints that TCR
interaction with antigen-expressing cells confers on the generation of
effective antiviral responses.
However, there are several limitations to the peripheral redirec-
tion approach that may hinder its therapeutic development in HIV
disease. The ex vivo manipulation of mature T cells inherent in this
strategy can functionally alter the cells and result in subsequent and
important effects on cellular differentiation in vivo following reinfu-
sion. As recent studies suggest, cellular differentiation phenotypes
and methods of in vitro manipulation of peripheral T cells can have
dramatic effects in functional outcomes following handling (Hinrichs
et al., 2011; Kaneko et al., 2009; Zhang et al., 2007). Further, ex vivo
manipulation has a signiﬁcant impact on the lifespan of the cells once
reinfused back in the body (Berry et al., 2009). A particular problem
with the introduction of antigen-speciﬁc TCRs involves the fact that
the altered cells retain the expression of their endogenous T cell
receptors. Modiﬁcation of peripheral T cells with a cloned TCR could
result in cross-receptor paring with the expressed endogenous TCR,
producing mixed TCR α and β chain pairs. This could produce self-
reactive T cells by overriding peripheral tolerance mechanisms since
these cells expressing these cross-paired TCR chains are not subjected
to normal thymic negative selection processes. There is evidence to
suggest that this mechanism may contribute to graft-versus-host
disease (GVHD) in a mouse model that involved the modiﬁcation of
mouse peripheral T cells with a cloned TCR, where mixed TCRs were
produced and resulted in autoreactive cells (Bendle et al., 2010). In
addition, a study that introduced human TCRs into human peripheral
T cells demonstrated the formation of alloreactive cells expressing
mixed TCRs in vitro (van Loenen et al., 2010). However, while these
studies show that this is a potential consequence of introduced TCR in
peripheral T cells expressing an endogenous TCR and that this
approach must be performed in humans with careful safeguards,
cross-pairing of TCRs may be limited to certain settings as the
generation of GVHD does not appear to occur following autologous
reinfusion of TCR modiﬁed T cells in human clinical trials (Rosenberg,
2010). In addition, methods to optimize transgenic α and β pairing
may bypass or reduce the likelihood of this scenario (Govers et al.,
2010). As will be discussed below, an approach utilizing human HSCs
may overcome many of these problems by allowing natural
developmental mechanisms to produce genetically engineered
immune cells that target HIV infection that are tolerant of the host
and possess prolonged self-renewal capability.
Stem cell-based immune programming
The fact that the immune system is incapable of naturally
eradicating HIV infection mandates that a successful immune-based
therapeutic strategy would allow long-lived, renewable immune
responses capable of generating the quantity of antiviral cells and
quality needed to allow complete eradication of HIV from the body. A
new focus on this approach is the utilization of human HSCs that
would allow the development of immune cells capable of targeting
HIV. The use of a HSC-based therapeutic approach would allow
multilineage hematopoietic development and the potential of target-
ing one or more of these arms of the immune response towards HIV.The development of these genetically modiﬁed, HIV-targeted cells
from HSCs in the body following normal cellular differentiation
pathways would allow proper and normal “education” and selection
of these cells to produce cells that would, theoretically, be physio-
logically like unmodiﬁed cells. Thus, the activation and expansion of
antigen reactive cells in the periphery would allow the differentiation
of these cells into long-term memory cells through natural mecha-
nisms. Further, a HSC-based approach would allow long-term
engraftment of genetically modiﬁed cells capable of generating
continual lymphopoietic development of antigen-naïve HIV-targeted
cells, potentially repairing defects in exhausted HIV-speciﬁc cells.
They would thus lack the issues of functional impairment, develop-
mental biasing, or exhaustion that other peripheral cell ex vivo
modiﬁcation methods would have. A human stem cell-based
approach is one of the more recent to gain impetus and one of the
more difﬁcult strategies to develop due to the paucity of experimental
systems that allow the close examination of human hematopoietic
events and cellular function. However, recent advances have been
made in the early development of HSC-based immune programming
as a viable therapeutic strategy.
One initial aim of stem cell-based immune therapeutic strategies
has focused on engineering the development of B cells that produce
neutralizing antibodies or CTL that target and kill HIV infected cells.
Recent studies have demonstrated the ability to program B cells
resultant from human HSCs to express an anti-HIV neutralizing
antibody following differentiation in vitro and differentiation in vivo in
humanized mice (Joseph et al., 2010; Luo et al., 2009). Further,
expression of the neutralizing antibody following development into B
cells in vivo in humanized mice signiﬁcantly lowered viral loads and
levels of infected cells (Joseph et al., 2010). While this approach using
a single monoclonal antibody would almost certainly drive viral
mutation in vivo, these studies provide the proof of principle that can
be further explored in the utilization of multiple antibodies directed
against HIV. Engineered B cell responses may be useful in enhancing
cellular immune responses, particularly in the mucosal and innate
immune compartments, and a therapeutic beneﬁt may be obtained
alone or in combination with other strategies. Further development in
this approach may provide insight in the development of other
chimeric receptors or single-chain therapeutic antibodies with
recognition domains that target cellular immunity towards HIV
infected cells (Roberts et al., 1994; Rossi et al., 2007; Yang et al., 1997).
Due to their importance in controlling HIV infection, engineering
HSCs to augment or enhance antiviral T cell immunity is another
enticing strategy for investigation as a potential therapeutic approach.
Studies performed inmice examining antigen-speciﬁc T cell responses
utilizing transgenic mice that express a mouse TCR speciﬁc to one of a
variety of antigens provide a basis for exploring this type of genetic
modiﬁcation in human cells (Pircher et al., 1989; Tian et al., 2007).
Further, mouse-based studies demonstrated that mouse HSCs
modiﬁed with cloned mouse TCRs can develop into antigen-speciﬁc
T cells in vivo (Yang and Baltimore, 2005; Yang et al., 2002). Early
studies with human cells demonstrated the ability of human HSCs to
develop into T cells following differentiation on murine Delta-like 1
molecule-expressing stromal cell lines (van Lent et al., 2007; Zhao et
al., 2007). However, the resultant cells in these studies that expressed
the transgenic TCR did not undergo normal positive and negative
selection events that a developing T cell would encounter in the
human thymic environment. In what we believe is a major step
forward in this approach, we recently determined that a molecularly
cloned TCR speciﬁc for the SL9 peptide allows the development of
functional HIV-speciﬁc CTL in human thymus tissue in vivo in SCID-hu
mice (Kitchen et al., 2009). This TCR recognizes the SL9 epitope in the
context of HLA-A*0201, and we demonstrated the necessity for
expression of this allele in the thymus tissue to allow proper
development of CD8 single positive thymocytes. These studies are
the ﬁrst to demonstrate that a human TCR can allow the development
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vivo and further demonstrate the necessity of matching the cloned
TCR to the proper HLA type.
A therapeutic strategy involving molecularly cloned, antigen-
speciﬁc TCRs, much like with the modiﬁcation of peripheral blood T
cells with a cloned TCR, would therefore have to be tailored to the HLA
type of the individual receiving treatment in order to produce cells
that survive T cell selection processes. However, this process of
development and thymic positive and negative selection from HSC
progenitors would theoretically reduce the possibility of producing
cells that are autoreactive, bypassing amajor drawback of peripheral T
cell modiﬁcation. A further advantage of using a stem cell-based
approach is longer engraftment of functionally capable gene marked
cells than with peripheral cell-based modiﬁcation. As with the
necessity of utilizing multiple molecularly cloned monoclonal anti-
bodies for that approach to be a viable therapeutic strategy, multiple
TCRs targeted to different, relatively conserved epitopes of HIV within
deﬁned HLA molecules would likely reduce the possibility of viral
immune escape and increase the numbers of suppressive antiviral
CTLs. Identifying and further characterizing conserved HIV TCR
epitopes is important in the expansion and utilization of an
engineered T cell approach. Immune escape to avoid certain CTL
epitopes may render a ﬁtness cost to the virus, and therefore lower
the capacity of the virus to replicate. There is evidence that viral
evolution and immune escape to alter certain conserved epitopes
occurs relatively slowly, and immune pressure caused by T cell
responses engineered against them may be therapeutically beneﬁcial
in forcing the evolution of the virus into a less- ﬁt state (Althaus and
De Boer, 2008; Troyer et al., 2009).
Due to the technological development of more rapid antigen-
speciﬁc TCR identiﬁcation strategies (Balamurugan et al., 2010), itmay
become possible to developmultiple “off the shelf”molecularly cloned
TCRs to a variety of viral antigens in the context of different HLA types
that could be rapidly matched to the individual HLA type and viral
genotypes they possess. In addition, chimeric receptors, such as the
aforementioned UTR, may provide a way of allowing the generation of
antigen-speciﬁc cells outside of HLA restriction. Due to the fact that
natural antigen-speciﬁc TCR precursor cell frequencies are relatively
low and that a single precursor can produce thousands of antigen-
speciﬁc progeny cells (Harty and Badovinac, 2008;Wiesel et al., 2009),
it would not be necessary to achieve the high levels of genetic
transduction necessary to protect progeny cells from infection or to
redirect peripheral blood cells in other gene therapy models. A recent
study, using a highly sensitive, enrichment-based technique, identiﬁed
the naïve CD8+ T cell precursor frequency for the SL9 epitope in
uninfected HLA-A*0201 individuals as approximately one in 3.3 × 106
cells in the peripheral blood (Alanio et al., 2010). This precursor
frequency is similar to that of cells with a speciﬁcity to a variety of
other viral antigens. Increasing this naïve cell, HIV-speciﬁc precursor
frequency through molecularly cloned HIV-speciﬁc TCRs to conserved
epitopes of HIV could overcome limits in the magnitude of the CTL
response, reconstitute defects that appear in the ability of antigen-
speciﬁc cells to respondby supplying newlydeveloped, naïve cells, and
diversify the breadth of the responses by targeting new epitopes in
treated individuals. While the current preclinical development of this
approach is ongoing, engineering T cell immunity through the use of
molecularly cloned, HIV-speciﬁc TCRs and HSCs represents a potential
means to increase the quantity and quality of the CTL response in
infected individuals. With the ultimate goal of immune control of viral
replication, this approach could provide beneﬁt towards delaying or
preventing disease progression.
Conclusions
In sum, therapeutic strategies to treat HIV infection utilizing stem
cell-based approaches have recently become a major focus of interest.Recently published studies have demonstrated the reproducibility
and feasibility of performing genetic manipulation and transplanta-
tion of HSCs in an expanded clinical setting. There are currently
several therapeutic strategies under investigation that are aimed at
treating HIV infection by protecting the cell from infection or by
speciﬁcally engineering and targeting immune responses towards the
virus using adult-derived HSCs. Alternative approaches are also under
investigation that use stem cells derived from different sources. For
instance, there have been recent reports that human embryonic stem
cells (hESC) can differentiate into the major HIV target cells, T cells,
dendritic cells, and macrophages (Anderson et al., 2006; Bandi and
Akkina, 2008; Galic et al., 2006, 2009; Subramanian et al., 2009;
Timmermans et al., 2009). As further investigation into better
differentiation protocols for these cells allows this to become more
efﬁcient, it is potentially feasible that stem cells sourced from hESC as
well as induced pluripotent stem cells (iPSC) (Lowry et al., 2008; Park
et al., 2008; Takahashi et al., 2007; Yu et al., 2007) could be used for
gene therapeutic strategies to combatmultiple diseases, including HIV
infection. The coming years will likely see the development of greater
numbers of safety and efﬁcacy studies from the next generation of
stem cell-based therapeutic approaches that will serve as the basis
towards the use of these strategies in therapeutic applications for
many chronic diseases.
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